Our focus turns to EnteroMedics (NASDAQ:ETRM), which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics’ approach may be a better solution for people who see little or no…
Tag: VVUS
UPDATED: EnteroMedics (ETRM) Basic DD and Thesis
EnteroMedics Inc. (ETRM) I bought a nice amount of shares. Catalyst trade run up target opinion: $.4.40. Positive data release: Gap to $7. 1 year: $15 (my opinions only) According to company press releases, conference calls, and my correspondence with…
Charts and commentary on $ATHX and others + Trading analysis. Honor Dr. King today.
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. please note; the charts on the right side get cut off…
Athersys, Inc. (ATHX) Beginning Due Diligence (chart technicals to come in seperate post)
Beginning points of Due Diligence for Athersys (ATHX) I am long the stock from $1.24. My Short Term catalyst Price Target opinion is $1.55 to $1.75, and $2.75 based on if positive Phase II data is reported. Multiple 2013 Catalysts…
